Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects.

Jessurun NT, Drent M, van Puijenbroek EP, Bekers O, Wijnen PA, Bast A.

Curr Opin Pulm Med. 2019 Sep;25(5):468-477. doi: 10.1097/MCP.0000000000000590.

PMID:
31365381
2.

Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability.

Hendriks CMR, Saketkoo LA, Elfferich MDP, De Vries J, Wijnen PAHM, Drent M.

Lung. 2019 Aug;197(4):407-413. doi: 10.1007/s00408-019-00234-3. Epub 2019 May 17.

3.

Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects.

Jessurun NT, Drent M, van Puijenbroek EP, Bekers O, Wijnen PA, Bast A.

Curr Opin Pulm Med. 2019 May 6. doi: 10.1097/MCP.0000000000000590. [Epub ahead of print]

PMID:
31094717
4.

VKORC1 and CYP2C9 Polymorphisms: A Case Report in a Dutch Family with Pulmonary Fibrosis.

Wijnen P, Drent M, Bekers O, Verschakelen J, Bast A.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1160. doi: 10.3390/ijms20051160.

5.

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis.

de Brouwer B, Drent M, van den Ouweland JMW, Wijnen PA, van Moorsel CHM, Bekers O, Grutters JC, White ES, Janssen R.

Respir Res. 2018 Mar 20;19(1):45. doi: 10.1186/s12931-018-0747-6.

6.

Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias?

Drent M, Wijnen P, Bast A.

Curr Opin Pulm Med. 2018 May;24(3):287-295. doi: 10.1097/MCP.0000000000000467. Review.

PMID:
29538081
7.

Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study.

Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J.

Respir Med. 2018 May;138S:S24-S30. doi: 10.1016/j.rmed.2017.11.008. Epub 2017 Nov 20.

PMID:
29239767
8.

Acute eosinophilic pneumonia associated with glyphosate-surfactant exposure.

De Raadt WM, Wijnen PA, Bast A, Bekers O, Drent M.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jul 22;32(2):172-5.

PMID:
26278698
9.

Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population.

Cremers JP, Van Kroonenburgh MJ, Mostard RL, Vöö SA, Wijnen PA, Koek GH, Drent M.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):37-45.

PMID:
24751452
10.

Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis.

Wijnen PA, Cremers JP, Nelemans PJ, Erckens RJ, Hoitsma E, Jansen TL, Bekers O, Drent M.

Eur Respir J. 2014 Jun;43(6):1730-9. doi: 10.1183/09031936.00169413. Epub 2014 Feb 20.

11.

Body composition profiling in a Dutch sarcoidosis population.

Cremers JP, Drent M, Elfferich MD, Nelemans PJ, Wijnen PA, Witteman BJ, Schols AM.

Sarcoidosis Vasc Diffuse Lung Dis. 2013 Dec 17;30(4):289-99.

PMID:
24351620
12.

Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis.

Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Vöö S, Drent M.

Respir Med. 2013 Mar;107(3):439-47. doi: 10.1016/j.rmed.2012.11.011. Epub 2012 Dec 19.

13.

Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger?

Wijnen PA, Verschakelen JA, Bast A, Bekers O, Drent M.

Lung. 2013 Feb;191(1):53-9. doi: 10.1007/s00408-012-9436-2. Epub 2012 Nov 13.

PMID:
23149804
14.

A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Mostard RL, Van Kuijk SM, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Drent M.

BMC Pulm Med. 2012 Sep 14;12:57. doi: 10.1186/1471-2466-12-57.

15.

Interstitial lung damage due to cocaine abuse: pathogenesis, pharmacogenomics and therapy.

Drent M, Wijnen P, Bast A.

Curr Med Chem. 2012;19(33):5607-11. Review.

PMID:
22934773
16.

Therapeutic approach of hepatic sarcoidosis.

Cremers JP, Drent M, Baughman RP, Wijnen PA, Koek GH.

Curr Opin Pulm Med. 2012 Sep;18(5):472-82. Review.

PMID:
22617809
17.

Cat litter is a possible trigger for sarcoidosis.

Drent M, Wijnen PA, Boots AW, Bast A.

Eur Respir J. 2012 Jan;39(1):221-2. doi: 10.1183/09031936.00074411. No abstract available.

18.

F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients.

Mostard RL, Prompers L, Weijers RE, van Kroonenburgh MJ, Wijnen PA, Geusens PP, Drent M.

Clin Nucl Med. 2012 Jan;37(1):21-5. doi: 10.1097/RLU.0b013e3182335f9b.

PMID:
22157023
19.

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M.

Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713-20. doi: 10.1007/s00417-011-1844-0. Epub 2011 Nov 27.

20.

Liver-test abnormalities in sarcoidosis.

Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R, Koek G.

Eur J Gastroenterol Hepatol. 2012 Jan;24(1):17-24. doi: 10.1097/MEG.0b013e32834c7b71.

PMID:
22008629
21.

Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.

Mostard RL, Vöö S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M.

Respir Med. 2011 Dec;105(12):1917-24. doi: 10.1016/j.rmed.2011.08.012. Epub 2011 Sep 6.

22.

Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers.

Wijnen PA, Bekers O, Drent M.

Mol Diagn Ther. 2011 Jun 1;15(3):177-80. doi: 10.2165/11591080-000000000-00000.

PMID:
21766908
23.

Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis.

de Kleijn WP, De Vries J, Wijnen PA, Drent M.

Respir Med. 2011 Sep;105(9):1388-95. doi: 10.1016/j.rmed.2011.05.004. Epub 2011 Jun 23.

24.

Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression?

Wijnen PA, Voorter CE, Nelemans PJ, Verschakelen JA, Bekers O, Drent M.

Hum Immunol. 2011 Apr;72(4):342-7. doi: 10.1016/j.humimm.2011.01.011. Epub 2011 Jan 20.

PMID:
21256912
25.

Relationship between drug-induced interstitial lung diseases and cytochrome P450 polymorphisms.

Wijnen PA, Bekers O, Drent M.

Curr Opin Pulm Med. 2010 Sep;16(5):496-502. doi: 10.1097/MCP.0b013e32833c06f1. Review.

PMID:
20592596
26.

Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment.

Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M.

Respiration. 2010;80(3):212-9. doi: 10.1159/000314225. Epub 2010 Apr 29.

27.

Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants.

Wijnen PA, Linssen CF, Haenen GR, Bekers O, Drent M.

Mol Diagn Ther. 2010 Feb 1;14(1):23-30. doi: 10.2165/11530890-000000000-00000.

PMID:
20121287
28.

The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis.

Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M.

Tissue Antigens. 2010 Mar;75(3):262-8. doi: 10.1111/j.1399-0039.2009.01437.x. Epub 2010 Jan 11.

PMID:
20070603
29.

Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.

Wijnen PA, Limantoro I, Drent M, Bekers O, Kuijpers PM, Koek GH.

Ann Clin Biochem. 2009 Nov;46(Pt 6):527-30. doi: 10.1258/acb.2009.009003. Epub 2009 Oct 12.

PMID:
19822698
30.

Pharmacogenetic testing after a simple DNA isolation method on buccal swab samples.

Wijnen PA, Drent M, van Dieijen-Visser MP, Bekers O.

Pharmacogenomics. 2009 Jun;10(6):983-7. doi: 10.2217/pgs.09.4.

PMID:
19530965
31.

Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands.

Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, Haenen GR, Bekers O.

Drug Saf. 2008;31(12):1125-34. doi: 10.2165/0002018-200831120-00008.

PMID:
19026029
32.

Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.

Wijnen PA, Op den Buijsch RA, Drent M, Kuijpers PM, Neef C, Bast A, Bekers O, Koek GH.

Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:211-9. doi: 10.1111/j.1365-2036.2007.03490.x. Review. Erratum in: Aliment Pharmacol Ther. 2009 Feb 1;29(3):350. Kuipers, P M J C [corrected to Kuijpers, P M J C].

33.

Genotyping with a dried blood spot method: a useful technique for application in pharmacogenetics.

Wijnen PA, Op den Buijsch RA, Cheung SC, van der Heijden J, Hoogtanders K, Stolk LM, van Dieijen-Visser MP, Neef C, Drent M, Bekers O.

Clin Chim Acta. 2008 Feb;388(1-2):189-91. Epub 2007 Oct 10.

PMID:
18028890
34.

Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis.

Veltkamp M, Wijnen PA, van Moorsel CH, Rijkers GT, Ruven HJ, Heron M, Bekers O, Claessen AM, Drent M, van den Bosch JM, Grutters JC.

Clin Exp Immunol. 2007 Sep;149(3):453-62. Epub 2007 Jun 12.

35.

Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.

Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS, Leung KT, Kwan TH, de Vrie JE, Wijnen PA, van Dieijen-Visser MP, Bekers O.

Pharmacogenomics. 2006 Jun;7(4):563-74.

PMID:
16753004
36.

Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays.

Op den Buijsch RA, Wijnen PA, van Dieijen-Visser MP, de Vries JE, Bekers O.

Pharmacogenomics. 2005 Jun;6(4):393-7.

PMID:
16004557
37.

Genotyping of the PXR A11156C polymorphism with locked nucleic acid containing fluorogenic probes.

Op den Buijsch RA, de Vries JE, Loots WJ, Landt O, Wijnen PA, van Dieijen-Visser MP, Bekers O.

Pharmacogenomics J. 2005;5(2):72-4. No abstract available.

PMID:
15772695
38.

Determination of the degree of substitution and its distribution of carboxymethylcelluloses by capillary zone electrophoresis.

Oudhoff KA, Buijtenhuijs FA, Wijnen PH, Schoenmakers PJ, Kok WT.

Carbohydr Res. 2004 Aug 2;339(11):1917-24.

PMID:
15261584
39.

[Discipline tribunal? Yes! But with the correct rules!].

Wijnen P.

Tijdschr Diergeneeskd. 2002 Dec 15;127(24):767-9. Dutch. No abstract available.

PMID:
12516390
40.

Capillary electrophoretic detection in apolipoprotein E genotyping.

Bekers O, op den Buijsch RA, de Vries JE, Wijnen PA, van Dieijen-Visser MP.

Electrophoresis. 2002 Jun;23(12):1878-81.

PMID:
12116131
41.

PCR on cell lysates obtained from whole blood circumvents DNA isolation.

de Vries JE, Wijnen PA, Hamulyák K, van Dieijen-Visser MP, Bekers O.

Clin Chem. 2001 Sep;47(9):1701-2. No abstract available.

42.

Flurbiprofen, S(+), eyedrops: formulation, enantiomeric assay, shelf-life and pharmacology.

van Sorge AA, Wijnen PH, van Delft JL, Coré-Bodelier VM, van Haeringen NJ.

Pharm World Sci. 1999 Apr;21(2):91-5.

PMID:
10380237
43.

Capillary electrophoresis of serum proteins. Reproducibility, comparison with agarose gel electrophoresis and a review of the literature.

Wijnen PA, van Dieijen-Visser MP.

Eur J Clin Chem Clin Biochem. 1996 Jul;34(7):535-45. Review.

PMID:
8864402
44.

Biodegradation of alpha- and beta-hexachlorocyclohexane in a soil slurry under different redox conditions.

Bachmann A, Walet P, Wijnen P, de Bruin W, Huntjens JL, Roelofsen W, Zehnder AJ.

Appl Environ Microbiol. 1988 Jan;54(1):143-9.

Supplemental Content

Loading ...
Support Center